Southeast Cancer Control Consortium, Inc

描述（由申请人提供）：东南癌症控制联盟公司（SCCC）， CCOP自1987年以来一直由国家癌症研究所（NCI）资助。SCCC是一个由东南部五州地区的20个组成部分/24个机构组成的财团。SCCC的长期目标是将最先进的临床试验带到社区机构的舞台上，以增加获得机会。转诊社区的集水区估计有840万，人口结构反映出人口密度低，社会经济和教育发展有限，女性比例大于50%，非洲裔美国人与白人人口的比例几乎是全国平均水平的两倍。共有155名医生参与。每个组成部分都有指定的“社区领导”（CL）和“研究协调员”（SC），负责参与医生和研究团队之间的项目协调。研究团队由肿瘤护士和临床研究助理（CRAs）组成，由SCCC运营办公室培训，符合联邦和研究基地（RB）法规。SCCC业务办公室协调活动，提供：电话/传真/电子邮件信息；为RBs提供文档和查询的网站；机构审查委员会（IRB）审批监督；RB协议半月邮件；进行组件的现场访问；数据管理培训/继续教育项目；准备拨款申请及报告；协调RB审核。SCCC运营办公室为组件提供来自8个RBs的临床试验。每个组成部分确定适用于其区域的研究，并由人类研究保护办公室（OHRP）授权的当地IRB授予批准。示范课程和示范课程对试点进行教育和促进。庞大的网络为医生提供了最先进的癌症项目，因此患者/参与者可以获得最新的选择。目标是通过增加参与癌症研究的医生数量，并遵守方案指南，克服参与临床试验的种族、少数民族、性别和社会经济障碍，降低癌症的发病率和死亡率。

DESCRIPTION (provided by applicant): The Southeast Cancer Control Consortium, Inc. (SCCC), CCOP has been funded by the National Cancer Institute (NCI) since 1987. The SCCC is a consortium of 20 components/24 institutions in a five-state area of the southeast. The SCCC's long-term objective is to bring state-of-the-art clinical trials to an arena of community institutions to increase access. The catchment of the referral communities is estimated at 8.4 million, with demographics reflecting a low population density, limited socioeconomic and educational development, female percentage greater than 50%, and ratio of African American to white population almost twice the national average. There are 155 participating physicians. Each component has a designated "Community Leader" (CL) and "Study Coordinator" (SC) responsible for coordination of the program among participating physicians and the research team. The research team is comprised of oncology nurses and clinical research associates (CRAs) trained by the SCCC Operations Office in compliance to federal and research base (RB) regulations. The SCCC Operations Office coordinates the activities by providing: telephone/fax/email information; website that supplies documents and queries for RBs; Institutional Review Board (IRB) approvals monitoring; RB protocol semimonthly mailings; conduction of component on-site visits; data management training/continuing education programs; preparation of grant applications and reports; and coordination of RB audits. The SCCC Operations Office provides the components with clinical trials from eight RBs. Each component determines the studies applicable to their area and the local IRB, which is authorized by the Office for Human Research Protections (OHRP), grants approval. The CLs and SCs educate and facilitate trial implementation. The expansive network supplies physicians' access to the most advanced level of cancer programs, so patients/participants may access current options. The goal is to reduce morbidity and mortality of cancer by overcoming ethnic, minority, gender, and socioeconomic barriers to clinical trial participation through increasing the number of physicians participating in cancer research with compliance maintained in protocol guidelines. RELEVANCE: The mission is to offer access to clinical trials, thus improving the quality of cancer treatment, reducing the incidence through prevention education, and reducing morbidity and mortality through early diagnosis. The opportunity to impart knowledge to minority groups, women, and underserved populations in rural communities increases the chance for these individuals to have comparable medical access.